1+ day, 10+ hour ago   (53+ words) Triple-negative breast cancer is the form of the disease that clinicians fear most. Lacking the three molecular targets — the estrogen receptor, the progesterone receptor and the HER2 protein — that anchor modern targeted therapies, it leaves patients with fewer options and a…...

1+ day, 12+ hour ago   (583+ words) Cancer immunotherapy has transformed the treatment landscape for many patients with solid tumors, delivering durable responses in diseases that once resisted nearly every therapeutic approach....

1+ day, 15+ hour ago   (71+ words) Aggressive non-Hodgkin lymphoma remains one of the most stubborn challenges in modern hematology. Even with a therapeutic arsenal that now includes rituximab-based immunochemotherapy, targeted kinase inhibitors, immune checkpoint blockade, and chimeric antigen receptor T-cell therapies, a substantial fraction of patients…...

1+ day, 17+ hour ago   (574+ words) One of the most persistent questions in modern lung cancer care has just received a sobering answer....

1+ day, 20+ hour ago   (753+ words) A sweeping community survey in central Uganda has revealed that public awareness of the mythical causes of cancer is strikingly low, with residents endorsing a wide range of unproven exposures as genuine carcinogens while failing to recognise them as myths....

1+ day, 22+ hour ago   (632+ words) Hemophagocytic lymphohistiocytosis is one of the most feared syndromes in medicine, a runaway immune firestorm in which the body’s own scavenger cells turn against blood cells and organs, and it can kill within weeks if untreated....

3+ day, 15+ hour ago   (779+ words) The immune system’s ability to hunt down and destroy cancer cells depends on a delicate molecular recognition process, one that acute myeloid leukemia has become disturbingly good at evading....

4+ day, 5+ hour ago   (718+ words) Immunotherapy has revolutionized the treatment of many cancers, and nowhere has its impact been more dramatic than in breast cancers that were once considered among the most difficult to treat....

4+ day, 9+ hour ago   (818+ words) A single number extracted from a routine MRI scan before treatment appears to predict how long patients with recurrent IDH-mutant gliomas will live without tumor progression after receiving bevacizumab, according to a new retrospective study from researchers at the University…...

5+ day, 4+ hour ago   (89+ words) In a finding that could reshape how researchers think about pairing targeted cancer drugs with immunotherapy, a team based at Taipei Veterans General Hospital and National Yang Ming Chiao Tung University has shown that cobimetinib, an approved MEK inhibitor best…...